Hematologic Malignancy Clinical Trials in Philadelphia, Pennsylvania
5 studies are recruiting for hematologic malignancy in Philadelphia, Pennsylvania right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.
Search these by distance from you
Studies now recruiting
-
Prospective Evaluation Of Delayed Effects Of Pediatric Car T Cell Therapy
This study is being done to learn more about the short-term and long-term side effects of CAR-T cell therapy. Specifically, researchers want to know how often patients get infections, have delays in recovering blood cell counts and/or have damage to the nervous system.
- Stage
- Not phased
- Ages
- Up to 30
- Site
- Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
- Locations
- 6 in total
- Run by
- St. Jude Children's Research Hospital
-
Allergy Delabeling in Antibiotic Stewardship - Intervention
The overall goal of the RENEW-IN intervention is to assess the impact of a BL allergy delabeling intervention on antibiotic use and clinical outcomes in patients with a hematologic malignancy.
- Stage
- Phase 4
- Ages
- 18 and older
- Site
- Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania
- Run by
- Abramson Cancer Center at Penn Medicine
-
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
The use of venetoclax-based therapies for pediatric patients with relapsed or refractory malignancies is increasingly common outside of the clinical trial setting. For patients who cannot swallow tablets, it is common to crush the tablets and dissolve them in liquid to create a solution. However, n…
- Stage
- Not phased
- Ages
- 0 to 38
- Site
- Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
- Locations
- 5 in total
- Run by
- Children's Hospital Medical Center, Cincinnati
-
Home Blood Transfusions
This is a pilot single arm study to evaluate the feasibility and acceptability of a home blood transfusion program. Patients will be enrolled with hematologic malignancies and other bone marrow failure syndromes who are transfusion dependent and interested in a home blood transfusion program. Parti…
- Stage
- Not phased
- Ages
- 18 and older
- Site
- Thomas Jefferson University Hospital, Philadelphia, Pennsylvania
- Run by
- Thomas Jefferson University
-
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Tagraxofusp is a protein-drug conjugate consisting of a diphtheria toxin redirected to target CD123 has been approved for treatment in pediatric and adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). This trial aims to examine the safety of this novel agent in pediatric patie…
- Stage
- Phase 1
- Ages
- 1 to 21
- Site
- Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
- Locations
- 31 in total
- Run by
- Therapeutic Advances in Childhood Leukemia Consortium
How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.
What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.
Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.